News | Breast Imaging | January 06, 2021

Transaction accelerates Hologic’s entry into oncology growth market, provides new lab capabilities

Transaction accelerates Hologic’s entry into oncology growth market, provides new lab capabilities

Getty Images


January 6, 2021 — Hologic, Inc., a global leader in women's health, announced today that it has agreed to acquire Biotheranostics, Inc., a privately held, commercial-stage company that provides molecular diagnostic tests for breast and metastatic cancers, for approximately $230 million, subject to working capital and other customary closing adjustments.

“Acquiring Biotheranostics enables us to jump-start our entry into a large, fast-growing oncology adjacency that fits perfectly with our broader corporate focus and passion for women’s health,” said Kevin Thornal, Hologic’s Division President, Diagnostics. “Together with the Biotheranostics team, we can leverage our commercial capabilities and expertise in molecular diagnostics automation to accelerate growth, help physicians make more informed decisions, and deliver more personalized treatment and better clinical outcomes for more women. In addition, Biotheranostics’ CLIA (Clinical Laboratory Improvement Amendments) lab provides us new capabilities to help accelerate market development for innovative new tests.”

“We are thrilled that the Biotheranostics team will become part of Hologic’s diagnostic business,” said Don Hardison, Biotheranostics’ President and Chief Executive Officer. “Hologic’s leadership in women’s health and molecular automation will accelerate access for both of our novel, proprietary tests, translating into better clinical outcomes for cancer patients. For Breast Cancer Index (BCI), our long-held belief is that all women who are being treated with endocrine therapy for their breast cancer deserve to know what is right for them. Being part of Hologic only helps bring that hope closer to reality. In addition, patients facing the challenges of metastatic cancer will have broader access to our CancerTYPE ID offering that can aid in the diagnosis of the tumor type and subtypes representing 95% of all solid tumors.”

Both of Biotheranostics’ tests are PCR (polymerase chain reaction)-based gene expression tests that have been extensively validated in large studies in areas of oncology with critical unmet needs and high growth potential. The BCI test is included in several clinical practice guidelines for breast cancer, and both tests enjoy widespread reimbursement in the United States.

“Using our strong cash flow to further expand our core businesses into large, fast-growing adjacencies is a key goal of our capital deployment strategy,” said Steve MacMillan, Hologic’s Chairman, President and Chief Executive Officer. “Acquiring Biotheranostics leverages our strengths in molecular diagnostics and complements our leadership in breast health, while providing attractive growth and return on invested capital.”

Biotheranostics generated approximately $33 million of revenue in calendar 2020. The acquisition is expected to be slightly dilutive to Hologic’s non-GAAP earnings per share in fiscal 2021, break-even in 2022, and accretive thereafter.

The acquisition is expected to close in February of 2021, subject to antitrust clearance and other customary closing conditions.

For more information: www.hologic.com

Related Content

News | Mammography

October 27, 2021 — As part of Breast Cancer Awareness Month, Penn Medicine will be providing free breast cancer ...

Time October 27, 2021
arrow
News | Artificial Intelligence

October 27, 2021 — Scientists from Skoltech, Philips Research, and Goethe University Frankfurt have trained a neural ...

Time October 27, 2021
arrow
News | Information Technology

October 27, 2021 — The U.S. Food and Drug Administration (FDA), Health Canada, and the United Kingdom’s (UK) Medicines ...

Time October 27, 2021
arrow
News | Radiation Oncology

October 25, 2021 — A new study shows that system-level changes to the way cancer care is delivered can also eliminate ...

Time October 25, 2021
arrow
News | Digital Radiography (DR)

October 21, 2021 — Carestream Health will demonstrate advanced capabilities in digital radiography (DR) rooms at the ...

Time October 21, 2021
arrow
News | Women's Health

October 20, 2021 — In conjunction with ongoing Breast Cancer Awareness Month efforts, Hologic, Inc., an innovative ...

Time October 20, 2021
arrow
News | Mammography

October 19, 2021 — If Black women begin mammography screening every other year starting at age 40, breast cancer deaths ...

Time October 19, 2021
arrow
News | Artificial Intelligence

October 19, 2021 — South Korean artificial intelligence (AI) developer, VUNO Inc., announced that the company closed a ...

Time October 19, 2021
arrow
Videos | Coronavirus (COVID-19)

An example of popliteal artery thrombosis formation caused by COVID-19 (SARS-CoV-2). Coronavirus often caused thrombus ...

Time October 19, 2021
arrow
News | Radiographic Fluoroscopy (RF)

October 18, 2021 — Long Island Jewish Valley Stream of Valley Stream, N.Y., recently became the first healthcare ...

Time October 18, 2021
arrow
Subscribe Now